A Pancreatic Cancer Breakthrough, Lilly’s $25B Deal Spree, and a Trial That Halved a Stock

Weekly Biotechnology Roundup · June 1–8, 2026 · By the Vanderbilt Report Editorial Team

It was a week of extremes. Cancer researchers got the kind of data they wait a career for, while two small drugmakers watched years of work unravel in a single afternoon. Here’s what actually mattered in biotech over the past seven days—and why.

If you only had ten minutes to catch up on biotechnology this week, this is the list. The 2026 American Society of Clinical Oncology (ASCO) meeting delivered a result oncologists are calling historic, Eli Lilly kept spending its weight-loss fortune at a frankly startling pace, and the FDA’s growing willingness to question a drug’s safety profile reshaped two companies overnight. Below, each story is broken down in plain language, with the numbers that matter and links to the original reporting.

1. A pancreatic cancer drug nearly doubled survival—and stole the show at ASCO

NASDAQ: RVMD The headline of the week belonged to Revolution Medicines. At ASCO’s plenary session on May 31, investigators presented full Phase 3 results for daraxonrasib, an oral drug that switches off RAS—the faulty growth signal that drives most pancreatic tumors. The data were also published simultaneously in The New England Journal of Medicine.

In the RASolute 302 trial, patients with previously treated metastatic pancreatic cancer who took daraxonrasib lived a median of 13.2 months, compared with roughly 6.7 months for those on standard chemotherapy. The drug also doubled the time before tumors started growing again. Experts on the floor described the findings as “landscape-changing,” and one ASCO specialist called them a game changer for the disease. Pancreatic cancer has resisted progress for decades, which is exactly why a clean doubling of survival drew a standing ovation.

Revolution plans to take the data to the FDA to support approval as a new second-line standard of care. The drug already holds Breakthrough Therapy and Orphan Drug designations.

2. Eli Lilly is buying everything—now including vaccines

NYSE: LLY Flush with cash from Mounjaro and Zepbound, Eli Lilly spent the week extending what is shaping up to be the most aggressive acquisition year in its history. The company agreed to pay up to roughly $3.8 billion combined for three vaccine-focused startups—Curevo, LimmaTech Biologics, and Vaccine Company (VaxCo)—marking its return to infectious disease after about seven years away.

The logic, as Lilly framed it, is prevention: stopping infections that have been linked years later to conditions like multiple sclerosis and certain cancers. VaxCo’s lead program targets Epstein-Barr virus, while Curevo brings a shingles vaccine that could rival GSK’s Shingrix.

Zoom out and the scale is remarkable. Since January, Lilly has announced or closed roughly 10 acquisitions worth about $25 billion—spanning in vivo CAR-T (Kelonia, Orna), sleep disorders (Centessa), and inflammation (Ventyx)—on top of its new oral GLP-1 pill, Foundayo (orforglipron), now reaching U.S. patients. The strategy is a hedge: diversify before the obesity gold rush slows and patents expire.

3. ADC Therapeutics: a trial that “worked” on paper crashed the stock

NYSE: ADCT Not every readout was a celebration. On June 3, ADC Therapeutics reported that its Phase 3 LOTIS-5 trial of Zynlonta plus rituximab in aggressive lymphoma (relapsed or refractory DLBCL) met its primary goal of slowing disease progression. But the trial recorded 27 deaths (13.2%) in the treatment arm versus 9 (4.6%) in the control group—roughly three times as many.

The market’s verdict was swift: shares fell more than 50% on June 4, sliding from around $3 to roughly $1.30. One analyst warned the death rate “may be difficult to accept” for physicians and regulators alike. Most of the deaths occurred in patients aged 75 and older. ADC still plans to meet with the FDA in August and file for expanded approval later in 2026, but it now faces a difficult benefit-versus-risk conversation.

4. Fulcrum Therapeutics laid off 85% of its staff after an FDA setback

NASDAQ: FULC The week’s starkest reminder that biotech is unforgiving came from Fulcrum Therapeutics. After the FDA flagged concerns about the benefit-risk profile of its lead sickle cell candidate, pociredir—pointing to safety signals seen across the same drug class—Fulcrum discontinued the program and announced it would cut about 85% of its workforce, shrinking from 57 employees to just 9.

Notably, this wasn’t a company running out of money: Fulcrum still reported more than $330 million in cash. Instead, it has shifted into preservation mode, hiring Leerink Partners to explore strategic alternatives such as a merger or sale. It’s a vivid example of regulators increasingly scrutinizing risk at the level of a drug’s mechanism, not just the individual molecule.

5. The IPO window is open: Parabilis targets up to $476M

NASDAQ: PBLS On the financing side, Parabilis Medicines (formerly FogPharma) set terms for one of the year’s largest biotech IPOs—25 million shares at $17 to $19 apiece, raising up to about $476 million. Proceeds will push its lead drug, zolucatetide, into Phase 3 testing for desmoid tumors, a rare and painful connective-tissue growth.

Parabilis is built around a “Helicon” peptide platform designed to reach historically undruggable targets inside cells. The offering adds to a genuinely strong year for new listings: 2026 has already seen biotech IPOs average more than $286 million in proceeds, a sharp rebound from the lean years that preceded it.

The week at a glance

Five companies, five very different outcomes. Here’s how the week’s biggest movers stacked up:

Quick hits

A few more moves worth noting from the week: Johnson & Johnson agreed to acquire Firefly Bio to bolster its oncology pipeline; Incyte moved to buy Vega Therapeutics; and Sanofi expanded its AI footprint through a new collaboration with Owkin. The throughline across all of it—deals, data, and downfalls alike—is a sector moving fast, with capital and regulators both raising the bar.

The takeaway

This week captured biotech in miniature: breakthrough science and brutal accountability sitting side by side. Daraxonrasib showed what’s possible when a long-elusive target finally cracks. Lilly demonstrated how obesity profits are reshaping the entire industry’s M&A map. And ADC and Fulcrum were reminders that “hitting the primary endpoint” no longer guarantees a happy ending—safety and regulatory judgment increasingly carry the day. For investors, patients, and founders, the message is the same: the bar for what counts as a win keeps rising.

• Revolution Medicines investor release & ASCO presentation — ir.revmed.com; ASCO — asco.org; analysis — BioPharma Dive; AJMC
• Eli Lilly vaccine deals & 2026 M&A — pharmaphorum; BioSpace; R&D World
• ADC Therapeutics LOTIS-5 — BioPharma Dive; Fierce Pharma; PharmaLive / Reuters
• Fulcrum Therapeutics restructuring — BioSpace; Fierce Biotech Layoff Tracker
• Parabilis Medicines IPO — BioSpace; pharmaphorum; BioPharma Dive

Disclaimer: This article is published by Vanderbiltreport.com for general informational and educational purposes only. It is a summary of publicly reported biotechnology news and does not constitute financial, investment, medical, or legal advice. Stock tickers and price movements are referenced for context only and should not be interpreted as a recommendation to buy, sell, or hold any security. Clinical trial results, regulatory outcomes, and corporate transactions described here may change as new information becomes available. Always consult a qualified financial advisor before making investment decisions and a licensed healthcare professional regarding any medical condition or treatment. Vanderbiltreport.com makes no warranty as to the accuracy or completeness of third-party reporting and is not responsible for the content of external sources linked above. All trademarks and company names are the property of their respective owners.